TALEN

TALEN1-asxl1

ID

ZDB-TALEN-191007-1

Name

TALEN1-asxl1

Previous Names

None

Target

asxl1 (1)

Target Sequence 1

5' - TGGAGAACTTTTCTGATG - 3'

Target Sequence 2

5' - TGACATGTAGAATCTGT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zdf34	asxl1
zdf35	asxl1

Expression

Gene expression in Wild Types + TALEN1-asxl1

No data available

Phenotype

Phenotype resulting from TALEN1-asxl1

No data available

Phenotype of all Fish created by or utilizing TALEN1-asxl1

Phenotype	Fish	Conditions	Figures
hepatocyte crowded, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
liver morphology, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
intestine morphology, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
whole organism adaxial-abaxial axis decreased size, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 1. from Gjini et al., 2019
whole organism anterior-posterior axis decreased size, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 1. from Gjini et al., 2019
head kidney erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. S2 from Gjini et al., 2019
intestine hypoplastic, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
intestinal villus truncated, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
muscle cell disorganized, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
liver hypoplastic, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
caudal hematopoietic tissue myb expression decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 3. from Gjini et al., 2019
hepatocyte vacuolated, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
trunk bida expression increased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 5. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 3. , Fig. 4. , Fig. 5. from Gjini et al., 2019
trunk bcl2l11 expression increased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 5. from Gjini et al., 2019
hepatocyte anatomical boundary amorphous, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
intestine nucleus irregular spatial pattern, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
muscle atrophied, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
whole organism decreased life span, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 1. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 4. from Gjini et al., 2019
developmental growth arrested, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 1. from Gjini et al., 2019
hepatocyte structure, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 4. , Fig. 5. from Gjini et al., 2019
hematopoietic system physical object quality, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. S2 from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 4. from Gjini et al., 2019
muscle nucleus circular, abnormal	asxl1^zdf34/zdf34	standard conditions	Fig. 2. from Gjini et al., 2019
blood myeloblast increased amount, abnormal	asxl1^zdf35/zdf35	standard conditions	Fig. 4. from Gjini et al., 2019
head kidney myeloblast increased amount, abnormal	asxl1^zdf35/zdf35	standard conditions	Fig. 4. from Gjini et al., 2019
hemopoiesis disrupted, abnormal	asxl1^zdf35/zdf35	standard conditions	Fig. 4. from Gjini et al., 2019
head kidney erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/+	standard conditions	Fig. 6. from Gjini et al., 2019
caudal hematopoietic tissue myb expression decreased amount, abnormal	asxl1^zdf34/+	standard conditions	Fig. 3. from Gjini et al., 2019
whole organism decreased life span, abnormal	asxl1^zdf34/+	standard conditions	Fig. 1. from Gjini et al., 2019
blood erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/+	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney common myeloid progenitor increased amount, abnormal	asxl1^zdf34/+	standard conditions	Fig. 6. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression amount, ameliorated	asxl1^zdf34/zdf34 + MO1-bida	standard conditions	Fig. 5. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell amount, ameliorated	asxl1^zdf34/zdf34 + MO1-bida	standard conditions	Fig. 5. from Gjini et al., 2019
head kidney common myeloid progenitor increased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/+	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/+	standard conditions	Fig. 6. from Gjini et al., 2019
blood common myeloid progenitor increased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/+	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney hematopoietic multipotent progenitor cell decreased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/+	standard conditions	Fig. 6. from Gjini et al., 2019
blood erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/+	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney myeloid leukaemia present, abnormal	asxl1^zdf34/+; tet2^zdf20/zdf20	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney hematopoietic multipotent progenitor cell increased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/zdf20	standard conditions	Fig. 6. from Gjini et al., 2019
head kidney common myeloid progenitor increased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/zdf20	standard conditions	Fig. 6. from Gjini et al., 2019
blood erythroid lineage cell decreased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/zdf20	standard conditions	Fig. 6. from Gjini et al., 2019
blood hematopoietic multipotent progenitor cell increased amount, abnormal	asxl1^zdf34/+; tet2^zdf20/zdf20	standard conditions	Fig. 6. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell myb expression amount, ameliorated	asxl1^zdf34/zdf34; bcl2l11^zdf19/zdf19	standard conditions	Fig. 5. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell amount, ameliorated	asxl1^zdf34/zdf34; bcl2l11^zdf19/zdf19	standard conditions	Fig. 5. from Gjini et al., 2019
hematopoietic multipotent progenitor cell decreased amount, abnormal	asxl1^zdf34/zdf34; zf169Tg	standard conditions	Fig. 3. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal	asxl1^zdf34/zdf34; zf169Tg	standard conditions	Fig. S5 from Gjini et al., 2019
hematopoietic multipotent progenitor cell apoptotic, abnormal	asxl1^zdf34/zdf34; zf169Tg	standard conditions	Fig. 3. from Gjini et al., 2019
hematopoietic multipotent progenitor cell EGFP expression decreased amount, abnormal	asxl1^zdf34/zdf34; zf169Tg	standard conditions	Fig. 3. from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell amount, ameliorated	asxl1^zdf34/zdf34; zf169Tg + MO1-bcl2l11	standard conditions	Fig. S5 from Gjini et al., 2019
caudal hematopoietic tissue hematopoietic multipotent progenitor cell amount, ameliorated	asxl1^zdf34/zdf34; zf169Tg + MO1-bida	standard conditions	Fig. S5 from Gjini et al., 2019

Citations